ULTRAGENYX PHARMACEUTICAL INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $653.8M | $433.6M |
| FY2020 | — | $1.15B | $713.5M |
| FY2021 | — | $922.6M | $307.6M |
| FY2022 | — | $352.0M | $132.9M |
| FY2023 | — | $275.0M | $214.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $653.8M | $433.6M |
| FY2020 | — | $1.15B | $713.5M |
| FY2021 | — | $922.6M | $307.6M |
| FY2022 | — | $352.0M | $132.9M |
| FY2023 | — | $275.0M | $214.0M |